首页> 外文OA文献 >Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

【2h】

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

机译：MEDI0562的安全性和临床活性，人源化的OX40激动剂单克隆抗体，成年患者晚期实体瘤患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Bonnie S. Glisson; Rom S. Leidner; Robert L. Ferris; John Powderly; Naiyer A. Rizvi; Bhumsuk Keam; Reva Schneider; Sanjay Goel; James P. Ohr; Jennifer Burton; Yanan Zheng; Steven Eck; Matthew Gribbin; Katie Streicher; Danielle M. Townsley; Sandip Pravin Patel;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors [J] . Glisson Bonnie S., Leidner Rom S., Ferris Robert L., Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第20期

机译：MEDI0562的安全性和临床活性，人源化的OX40激动剂单克隆抗体，成年患者晚期实体瘤患者
2. 30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors [J] . R.B.Cohen, N.J.Meropol, K.M.Padavic, European Journal of Cancer Supplements . 2004,第8期

机译：HGS-ETR1（针对TRAIL-R1的激动剂单克隆抗体）在晚期实体瘤患者中进行的30 A期临床试验
3. 30 A phase I clinical trial of HGS-ETR1, an agonist monoclonal antibody to TRAIL-R1, in patients with advanced solid tumors [J] . R.B.Cohen, N.J.Meropol, K.M.Padavic, European Journal of Cancer Supplements . 2004,第8期

机译：HGS-ETR1（针对TRAIL-R1的激动剂单克隆抗体）在晚期实体瘤患者中进行的30 A期临床试验
4. Characterization of cancer specific human monoclonal IgM antibodies produced by hybridomas derived from a patient with adult T-cell leukemia [C] . T. KAWAHARA, A. ICHIKAWA, Y. KATAKURA, Annual Meeting of the Japanese Association for Animal Cell Technology . 2002

机译：杂交瘤产生的癌症特异性人单克隆IgM抗体的表征衍生自成人T细胞白血病患者的杂交瘤
5. Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R) administered in combination with anticancer therapies to patients with advanced solid tumors [O] . V. M. Macaulay, M. R. Middleton, A. S. Protheroe, -1

机译：针对1型胰岛素样生长因子受体（IGF-1R）的人源化单克隆抗体AVE1642的I期研究与抗癌药物联合用于晚期实体瘤患者
6. Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors [O] . Elaine T. Lam, S. Gail Eckhardt, Wells Messersmith, 2017

机译：I阶段研究Enavatuzumab，靶向调节受体的一类级别的人源化单克隆抗体，在先进的实体瘤患者中

Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors

著录项

引文网络

相似文献

相关主题

期刊订阅